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ABSTRACT
Background    Merkel cell carcinomas (MCCs), clini-
cally aggressive neuroendocrine skin cancers, are divid-
ed into Merkel cell polyomavirus (MCPyV)-positive and 
-negative tumors, which show different clinicopatholog-
ical features and may develop through different mech-
anisms of carcinogenesis. Aberrant expression of acti-
vation-induced cytidine deaminase (AID) as a genomic 
modulator was demonstrated through pathogen-related 
NF-κB signal in Helicobacter pylori-associated gastric 
cancer, adult T cell leukemia/lymphoma (HTLV-1), hep-
atoma (HCV), and Burkitt lymphoma (EBV). 
Methods    To elucidate the relation of aberrant AID 
expression in MCPyV-positive and -negative MCCs, we 
evaluated immunohistochemical expressions of AID and 
AID-regulating factors between 24 MCPyV-positive and 
17 MCPyV-negative MCCs. 
Results    AID expression was significantly higher in 
MCPyV-negative MCCs than MCPyV-positive ones 
(P = 0.026), although expression of NF-κB p65 (phos-
pho S536) (AID-enhancer) was significantly higher in 
MCPyV-positive MCCs than MCPyV-negative ones 
(P = 0.034). Expressions of PAX5 and c-Myb were not 
significantly different between these subgroups. Expres-
sions of AID and AID-regulating factors were not cor-
related to prognosis of MCC patients. 
Conclusion    Our findings suggest that although 
pathogen-induced AID expression through upregula-
tion of NF-κB may be relevant to carcinogenesis of 
MCPyV-positive MCCs, the significantly higher aberrant 
AID expression in MCPyV-negative MCCs is consistent 
with the fact that MCPyV-negative MCCs have an ex-
tremely higher mutation burden than MCPyV-positive 
ones.
Key words    activation-induced cytidine deaminase; 
Merkel cell carcinoma; Merkel cell polyomavirus
Merkel cell carcinoma (MCC) is a clinically aggressive 
neuroendocrine skin cancer and Merkel cell polyoma-
virus (MCPyV) is monoclonally integrated into the 
genome of approximately 80% of MCCs.1 Recently, 
we demonstrated clinical and pathogenetic differences 
between MCPyV-positive MCCs and MCPyV-negative 
MCCs; MCPyV-positive MCCs have a more round 
and narrow shape than MCPyV- negative MCCs,2 and 
MCPyV-positive MCC showed a better prognosis than 
MCPyV-negative MCCs.3–5 However, it has not been ful-
ly elucidated how the tumorigenic mechanism or path-
way is different between MCPyV-positive and -negative 
MCCs.
 Activation-induced cytidine deaminase (AID), a 
nucleotide-editing enzyme, is essential for the somatic 
hypermutation (SHM) and class-switch recombination 
(CSR) of the immunoglobulin gene6 and evidence of 
AID’s involvement in carcinogenesis has been accumu-
lated in not only B-cell lymphoma but non-B cell malig-
nancy.6, 7 AID is a APOBEC family protein and induces 
off-target deamination of cytosine to uracil in DNA, 
and this AID-induced mutagenic U:G mismatch is 
considered as a common mutagenic mechanism in car-
cinogenesis.8 AID is also important as a genomic mod-
ulator in inflammation-associated cancer development 
in digestive organs including Helicobacter pylori (H. 
pylori)-associated gastric cancer, hepatitis C virus-pos-
itive hepatocellular carcinoma, colitis-associated colon 
cancers9 and pancreatic cancer.10 Nuclear factor-κB (NF-
κB) activation in epithelial cells and malignant cells 
is involved in generating genomic instability through 
aberrant AID expression, cell growth, proliferation, 
survival, angiogenesis, and epithelial-to-mesenchymal 
transition (EMT).11 Transcription and expression of AID 
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gene are controlled by many elements and transcription 
factors including NF-κB, Stat6, C/EBP, Smad3/4, Myb, 
Pax5, E2A, E2f and BATF, bind to the AID regulatory 
regions.12 The expression and activity of AID are tightly 
regulated at the levels of transcription, post-transcrip-
tion, and enzymatic function. Four distinct DNA regions 
(region I to IV) of the AID gene locus contain binding 
sites for multiple transcription factors. Region I func-
tions as a promoter containing the binding site for NF-
kB, a transcriptional activator. In B and non-B cells, 
enhancer elements in region II bind to the enhancer pro-
teins PAX5 (paired box gene 5) and E2A, while silencer 
elements in region II bind to the silencer proteins c-Myb 
and E2f in order to counter the activities of transcrip-
tional enhancers.12 Honjo et al. described pathogen-in-
duced AID expression in gastric cancer (H. pylori), adult 
T cell leukemia/lymphoma (ATLL) (HTLV-1), hepatoma 
(HCV), and Burkitt lymphoma (EBV), but not in clas-
sical Hodgkin’s lymphoma (EBV).6 However, aberrant 
AID expression in MCPyV-associated MCC has not yet 
been elucidated. MCPyV is an oncogenic agent in a set 
of MCCs.3 In this study, we evaluated and compared the 
expression of AID and AID-regulating factors such as 
NF-κB (enhancer), PAX5 (enhancer), and c-Myb (silenc-
er) between MCPyV-positive and –negative MCCs in or-
der to elucidate the association of MCPyV infection with 
expressions of AID and AID-regulating factors in the 
molecular pathogenesis of MCCs and clarify the ques-
tion whether or not MCPyV-induced AID expression is a 
causative factor of carcinogenesis in MCPyV-associated 
MCC.
MATERIALS AND METHODS
Samples
This study was approved by the Institutional Review 
Board of the Faculty of Medicine at Tottori Univer-
sity (No.1216). We used 24 MCPyV-positive and 17 
MCPyV-negative formalin-fixed paraffin- embedded 
(FFPE) MCC samples. 
MCPyV detection
To detect MCPyV infection, real-time quantitative poly-
merase chain reaction (q-PCR) and immunohistochem-
istry with antibody to MCPyV-Large T protein (CM2B4) 
were performed according to our previous studies.5, 13 
Immunohistochemistry
Immunohistochemistry staining was performed on 
4-μm-thick paraffin sections as described previous-
ly.14 Primary antibodies were used with the following 
dilutions: mouse monoclonal anti-AID (clone ZA001, 
dilution 1/200; Thermo Fisher Scientific, Waltham, 
MA), rabbit polyclonal anti-NF-κB p65 (phospho S536)
(1/500; Abcam, Cambridge, UK), rabbit monoclonal an-
ti-c-Myb (clone EP769Y, dilution 1/150; LSBio, Seattle, 
WA), mouse monoclonal anti-PAX5 (clone DAK-Pax5, 
dilution 1/30; Agilent Technologies, Santa Clara, CA). 
Antigen retrieval of a rabbit polyclonal anti-NF-κB p65 
(phospho S536) was performed by incubating the sec-
tions with target retrieval solution (pH 9.0) for 20 min-
utes, other antibodies were performed by incubating the 
sections with citrate buffer (pH 6.0) for 10 minutes using 
pressure cooker, then the immune complex was detected 
with an anti-mouse or anti-rabbit EnVision detection 
system and 3, 3´-diaminobenzidine and chromogenic 
substrate (DAKO).
 For evaluating immunohistochemistry, H-score was 
used as described previously.15
 The H-score is performed as the sum of the per-
centage of staining multiplied by an ordinal value corre-
sponding to the intensity level (0 = none, 1 = weak, 2 = 
moderate, 3 = strong). The resulting score ranged from 
0 (no staining in the tumor) to 300 (100% diffuse strong 
staining of the tumor).
Statistical analysis
Immunohistochemical findings were analyzed in re-
lation to MCPyV status using the Mann–Whitney U 
test. To identify baseline patient and AID, NF-κB p65 
(phospho S536), c-Myb and PAX5 associated with 
prognosis, univariate hazard ratios were calculated with 
95% confidence intervals (CIs) using the Cox propor-
tional-hazards model. The hazard ratio (HR) and 95% 
CI were estimated using Cox hazard regression analysis 
for overall survival (OS), disease-specific survival (DSS) 
and stratification for MCPyV status, AID, NF-κB p65(-
phospho S536), c-Myb and PAX5. The goodness of fit of 
each Cox model was evaluated using the likelihood ratio 
test, and the association between the individual variables 
and outcome was assessed using the forward Wald test 
selection (P ≤ 0.05 was selected for entry into the model, 
and P > 0.1 was selected for removal).
RESULTS
MCPyV detection
MCPyV infection in MCCs was confirmed by the 
presence of MCPyV-DNA with q-PCR and positive 
staining of MCPyV-Large T antigen (CM2B4) in tumor 
cells. And the clinicopathological characteristics of 24 
MCPyV-positive and 17 MCPyV-negative MCC cases 
are summarized in Table 1.
Immunohistochemical staining
The summary of immunohistochemical H-score for 
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Table 1. Clinical information of the patients in this study
Sample No. MCPyV(q-PCR)
Age
(years old) Sex
Tumor
size (cm)
Initial
treatment Organ Site Diagnosis Month
UK-M-1 – 81 F 4 RE Dermis Rt. shin Combined MCC & BD 7
UK-M-2 – 81 F 3.4 × 3 × 1.2 RE Dermis Rt. leg Combined MCC & BD 44
UK-M-3 – 85 F 2.1 RE Dermis Lower leg Combined MCC & SqCC 21
UK-M-4 – 93 F 5 RE Dermis Lt. cheek Combined MCC & SqCC 6
UK-M-8 – 87 F 1.4 RE Dermis Forehead Pure MCC 12
UK-M-10 – 94 F 6.5 × 5 × 2.5 PE Dermis Rt. lateral leg with multiple metastasis in the resion Pure MCC 16
UK-M-13 – 61 M 1.8 ×  1.5 RE Dermis Rt. shin Pure MCC 23
UK-M-14 – 86 F 1.5 ×  1.5 RE Dermis Lt. dorsam foot Combined MCC & BD 11
UK-M-20 – 82 M 3.5 RE, RD Dermis Rt. knee Combined MCC & BD 31
UK-M-5 – 81 F 3.5 PE Dermis Lt. leg with multiple satellites Combined MCC & SqCC 18
UK-M-23 (meta) – LN Lt. groin
UK-M-17 – 83 F 1.7 × 1.4 PE Dermis Lt. lower eyelid Combined MCC & BCC 39
UK-M-17 (meta) – Dermis Conjunctiva
UK-M-18 – 94 F 5 × 4 × 2 RD, RE Dermis Rt. temple Pure MCC 6
UK-M-31 (meta) – LN Rt. parotid 
MCC50 – 82 M 1.5 RE Dermis Dorsum of the hand Combined MCC & BD 13
MCC51 (meta) – LN Axilla
UK-M-7 + 68 M 2.7 × 1.7 × 0.8 RE Dermis Rt. knee Pure MCC 59
UK-M-9 + 69 M 5 ×  5 ×  4 RE Dermis Rt. groin Pure MCC 55
UK-M-11 + 61 F 1.2 RE Dermis Rt. cheek Pure MCC 18
UK-M-16 + 63 F 2.5 ×  2.5 RE, RD Dermis Lt. upper arm Pure MCC 70
UK-M-19 + 85 F 4 × 2.8 × 1.3 RE Dermis Rt. forearm Pure MCC 21
UK-M-22 + 74 F 6 × 5.5 × 2 RE Dermis Lt. elbow Pure MCC 72
MCC36 + 87 F 2 × 2.3 RE Dermis Nasal ala Pure MCC 3
MCC37 + 73 F 0.9 RE Dermis Cheek Pure MCC 29
MCC38 + 83 F 1.1 × 1.0 × 0.8 RE Dermis Cheek Pure MCC 2
MCC45 + 64 F 2 × 3 Unknown Dermis Lower thigh Pure MCC Unknown
MCC46 + 67 F 2 × 1.5 Unknown Hypodermis Buttock Pure MCC Unknown
MCC47 + 90 M 2 Unknown Dermis Humerus Pure MCC Unknown
MCC53 + 61 F 1.9 RE Dermis Earflap Pure MCC 28
MCC55 + 75 M 1.9 × 1.7 Unknown Dermis Cheek Pure MCC Unknown
MCC57 + 77 F Hen's egg size CT, RE Hypodermis Knee Pure MCC 53
MCC61 + 59 F 1.4 × 1.1 RE Dermis Lower thigh Pure MCC 35
MCC66 + 86 F 10 RD Dermis Superior eyelid Pure MCC 1
MCC70 + NA M 3 RE Dermis Thigh Pure MCC 34
MCC73 + 90 F 2 RD Dermis Cheek Pure MCC 3
MCC83 + 71 F 2 RE, RD Dermis Lt. thigh Pure MCC 31
UK-M-21 + 46 F 3 × 2.5 RE Dermis Lt. buttock Pure MCC 59
UK-M-21 (meta) + Dermis
MCC32 + 66 M 2 × 2.5 RE Dermis Thigh Pure MCC 2
MCC33 (meta) + LN Inguina
BD, Bowen’s disease; CT, chemotherapy; F, female; LN, lymph node; Lt., left; M, male; MCC, Merkel cell carcinoma; MCPyV, Merkel 
cell polyomavirus; meta, metastasis; NA, not available; PE, palliative excision; q-PCR, quantitative polymerase chain reaction; RD, radia-
tion; RE, radical excision; Rt., right; SqCC, squamous cell carcinoma.
AID, NF-κB p65 (phospho S536), PAX5 and c-Myb, 
and the representative immunostainings in the MCC 
subgroups are shown in Table 2, Figure 1, respectively. 
NF-κB p65 (phospho S536) was expressed only in the 
nuclei.
 AID expression was signif icantly lower in 
MCPyV-positive MCCs than MCPyV-negative ones 
(P = 0.026), although expression of NF-κB p65 (phos-
pho S536) (AID-enhancer) was significantly higher in 
MCPyV-positive MCCs than MCPyV-negative ones (P = 
0.034) (Table 3, Fig.2). There were no statistically signif-
icant differences between MCPyV-positivity in MCCs 
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and the other AID-regulating factors (PAX5 and c-Myb) 
(Table 3, Fig.2). 
 In addition, there was a statistically significant as-
sociation between AID and NF-κB p65 (phospho S536) 
Table 2. Summary of immunohistochemical H-scores for AID and AID-regulating factors  in MCPyV-positive and 
-negative MCCs 
q-PCR IHC IHC (H-score)
Sample No. MCPyV-DNA MCPyV-LT(CM2B4) AID
NF-κB p65
(phospho S536)
(AID-enhancer)
PAX5
(AID-enhancer)
c-Myb
(AID-silencer)
UK-M-1 – – 180 0 150 200
UK-M-2 – – 225 0 125 84
UK-M-3 – – 245 0 200 165
UK-M-4 – – 180 15 150 140
UK-M-8 – – 150 20 170 235
UK-M-10 – – 205 120 142 190
UK-M-13 – – 220 100 100 250
UK-M-14 – – 185 200 100 270
UK-M-20 – – 185 0 190 175
UK-M-5 – – 90 10 170 110
UK-M-23 (meta) – – 190 39 150 265
UK-M-17 – – 150 10 160 140
UK-M-17 (meta) – – 300 20 190 235
UK-M-18 – – 180 15 56 130
UK-M-31 (meta) – – 100 90 205 120
MCC50 – – 195 20 85 170
MCC51 (meta) – – 228 35 173 80
UK-M-7 + + 175 40 155 260
UK-M-9 + + 145 31 140 210
UK-M-11 + – 140 99 130 160
UK-M-16 + + 190 85 205 190
UK-M-19 + + 205 225 160 255
UK-M-22 + + 150 60 180 200
MCC36 + + 135 165 200 205
MCC37 + + 240 53 105 225
MCC38 + + 125 60 110 230
MCC45 + + 165 66 105 205
MCC46 + + 108 14 115 5
MCC47 + + 165 40 65 103
MCC53 + + 100 120 110 126
MCC55 + + 80 393 105 260
MCC57 + + 195 80 170 245
MCC61 + + 170 130 200 NA
MCC66 + + 70 40 200 245
MCC70 + + 190 30 180 87
MCC73 + + 215 240 240 93
MCC83 + + 185 190 170 150
UK-M-21 + + 250 10 90 150
UK-M-21 (meta) + + 280 11 170 260
MCC32 + + 120 30 180 130
MCC33 (meta) + + 90 55 90 145
AID, activation-induced cytidine deaminase; c-Myb, a member of MYV family; IHC, immunohistochemistry; LT, Large T antigen; 
MCC, Merkel cell carcinoma; MCPyV, Merkel cell polyomavirus; meta, metastasis; NA, not available; NE, not examined; NF-κB, Nu-
clear factor kappa-light-chain-enhancer of activated B cells; PAX5, Paired Box 5; q-PCR, quantitative polymerase chain reaction.
expressions (P < 0.05) but no statistically significant cor-
relations between AID and other AID-regulating factors 
(PAX5 or c-Myb) in MCCs.
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Table 3. Comparison of expressions of AID and AID-regulating factors in MCCs based on MCPyV status
Clinicopathological data MCPyV-positive MCCs MCPyV-negative MCCs P-value†
Age (y.o.; mean ± SD) 74.6 ± 9.8 83.3 ± 9.1 0.065
Sex (male/female) 6/16 3/10 0.56
Stage (I/ II/ III) 9/11/2 2/7/2 0.835
AID  H-score (mean ± SD) 157.4 ± 44.0 197.2 ± 27.4 0.026*
NF-κB p65 (phospho S536) H-score (mean ± SD) 108.1 ± 91.8 50.6 ± 68.3 0.034*
PAX5 H-score (mean ± SD) 152.3 ± 44.4 147.4 ± 33.5 0.627
c-Myb H-score (mean ± SD) 181.8 ± 69.2 189.9 ± 54.5 1
*Statistically significant. †Mann–Whitney U test.
AID, activation-induced cytidine deaminase; c-Myb, a member of MYV family; MCC, Merkel cell carcinoma; MCPyV, Merkel cell 
polyomavirus; NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cells; PAX5, Paired Box 5; y.o., years old.
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Fig. 1. Representative images of 
immunostaining of MCPyV-positive 
and MCPyV-negative MCCs. Rep-
resentative images of IHC of AID 
and AID-regulating factors [NF-κB 
p65 (phospho S536) (AID-enhancer), 
PAX5 (AID-enhancer), and c-Myb 
(AID-silencer)] in MCPyV-positive 
MCCs (A, C, E, G, I, and K) and 
MCPyV-negative MCCs (B, D, F, H, 
J, and L) are shown. MCPyV-neg-
ative MCC tumor cells (B) had 
more irregular nuclear shapes and 
more abundant cytoplasm than did 
MCPyV-positive MCC cells (A). 
MCPyV DNA-positive MCCs showed 
strong positive nuclear immunoreac-
tivity for MCPyV-LT (C), whereas 
MCPyV DNA–negative MCCs were 
negative for MCPyV-LT (D).  AID 
expression was observed with signifi-
cantly higher H-score in MCPyV-neg-
ative MCCs (F) than in MCPyV-pos-
itive MCCs (E) (H-score, mean ± SD, 
197.2 ± 27.4 versus 157.4 ± 44.0; P = 
0.026). NF-κB p65 (phospho S536) 
expression was significantly higher 
in MCPyV-positive MCCs (G) than 
in MCPyV-negative MCCs (H) (H 
score: mean ± SD, 108.1 ± 91.8 versus 
50.6 ± 68.3; P = 0.034). However, no 
significant differences were observed 
in the H-scores of PAX5 and c-Myb 
between MCPyV-positive and –nega-
tive MCCs. 
A and B, hematoxylin and eosin stain; 
A through L, IHC, scale bar = 25μm. 
AID, activation-induced cytidine de-
aminase; c-Myb, a member of MYV 
family; HE, hematoxylin-eosin; LT, 
Large T antigen; MCC, Merkel cell 
carcinoma; MCPyV, Merkel cell poly-
omavirus; NF-κB, Nuclear factor kap-
pa-light-chain-enhancer of activated 
B cells; PAX5, Paired Box 5.
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Statistical analysis for survival
Results of univariate and multivariate Cox regression 
analyses for all patients can be seen in Table 4. In uni-
variate analysis, MCPyV-positivity was a favorable 
parameter associated with a signifi cant increase of both 
OS (HR: 0.101, P = 0.001) and DSS (HR: 0.090, P = 
0.003), while male gender was signifi cantly unfavorable 
in DSS (HR: 0.090, P = 0.003) but not in OS (HR: 2.399, 
P = 0.250). With multivariate analysis, only the presence 
of MCPyV was found to be a significantly favorable 
prognostic factor for both OS (HR: 0.03, P < 0.001) and 
DSS (HR: 0.025, P = 0.006), while male gender and 
advanced stage (stage II and III) were signifi cantly unfa-
vorable only for OS (HR: 10.89, P = 0.045; HR: 14.39, P 
= 0.026, respectively). Expressions of AID and AID-reg-
ulating factors were not signifi cantly associated with OS 
and DSS.
DISCUSSION
AID expression of Merkel cell carcinoma with lymph-
node metastasis was reported in a case report.16 How-
ever, for the fi rst time, we focused to study on the asso-
ciation of expression of AID, a genomic mutator, with 
pathogenetic differences between MCPyV-positive and –
negative MCCs and demonstrated that MCPyV-negative 
MCCs showed a signifi cantly higher expression of AID 
than MCPyV-positive ones. This finding is consistent 
with the reported facts that MCPyV-negative MCCs dis-
played higher overall mutation burden than MCPyV-pos-
itive ones.17, 18
 Our previous studies showed some clinicopatholog-
ical differences between MCPyV-positive and -negative 
MCCs; MCPyV-positive MCCs showed a signifi cantly 
higher expression of retinoblastoma protein and less p53 
expression compared to MCPyV-negative MCCs, and 
frequency of TP53 non-ultraviolet signature mutation 
was signifi cantly higher in MCPyV-negative MCCs than 
in MCPyV-positive MCCs.4 And we also reported that 
Akt phosphorylation at T308 in activation of the Akt/
mammalian target of rapamycin (mTOR)/4E-binding 
protein 1 (4E-BP1) signaling pathway, was signifi cantly 
greater in MCPyV-negative than in MCPyV-positive 
MCCs19 and that lower expression of CADM1 and 
higher expression of MAL in MCCs are associated 
with MCPyV infection and better prognosis.15 It can be 
considered that MCPyV-positive and MCPyV-negative 
MCCs have different tumorigenic pathways; the integrat-
ed-mutated form of MCPyV is directly involved in “vi-
rus-mediated” tumorigenesis, whereas the accumulation 
of more complicating genetic aberrations is required for 
“nonviral” tumorigenesis; and both may develop under 
systemic/local impairment of host immune surveillance 
caused by UV irradiation, immunosenescence, use of 
immunosuppressants, and other factors.3
 Cancer cells are considered to be generated from the 
stepwise accumulation of genetic alterations in various 
genes in infl ammation-associated carcinogenesis.9 AID, 
a nucleotide-editing enzyme that is essential for SHM 
and CSR of the immunoglobulin gene, is also known 
to play a role as a genomic mutator in carcinogenesis.11 
AID	
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Fig. 2. Comparison of the immunohisto-
chemical H-score for AID, NF-κB p65 
(phospho S536), PAX5 and c-Myb between 
MCPyV-positive and -negative MCCs. 
AID expression was significantly lower in 
MCPyV-positive MCCs than MCPyV-neg-
ative ones (P = 0.026) while NF-κB p65 
(phospho S536) expression was signifi cantly 
higher in MCPyV-positive MCCs than 
MCPyV-negative ones (P = 0.034). No sta-
tistically signifi cant difference was observed 
on H-scores of PAX5 and c-Myb expression 
between MCPyV-positive and -negative 
MCCs. AID, activation-induced cytidine 
deaminase; c-Myb, a member of MYV fam-
ily; MCC, Merkel cell carcinoma; MCPyV, 
Merkel cell polyomavirus; NF-κB, Nuclear 
factor kappa-light-chain-enhancer of activat-
ed B cells; PAX5, Paired Box 5.
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Table 4. Univariate and multivariate cox proportional hazard analysis for mortality in MCC cases
Factors Overall survival MCC specific survival
Univariate analysis HR 95% CI P-value HR 95% CI P-value
Age (> 75/≤ 75 y.o.) 4.250 0.559–32.312 0.162 2.919 0.371–22.970 0.309 
Sex (male/female) 2.399 0.540–19.664 0.250 0.090 0.180–0.441 0.003 
Stage (stageII, III/stageI) 2.106 0.462–9.595 0.336 1.692 0.205–13.957 0.625 
MCPyV-positive/-negative 0.101 0.028–0.370 0.001 0.090 0.018–0.441 0.003 
AID  H-score (> 160 vs ≤ 160) 1.174 0.400–3.444 0.770 0.993 0.283–3.491 0.992 
NF-κB  H-score (> 65 vs ≤ 65) 0.834 0.287–2.423 0.739 0.718 0.188–2.742 0.628 
PAX5  H-score (> 130 vs ≤ 130) 1.448 0.465–4.512 0.523 2.147 0.462–9.985 0.330 
c-Myb  H-score (> 160 vs ≤ 160) 1.392 0.504–3.848 0.524 1.051 0.319–3.463 0.935 
Factors Overall survival MCC specific survival
Multivariate analysis HR 95% CI P-value HR 95% CI P-value
Age (> 75/≤ 75 y.o.) 0.23 0.010–5.166 0.356 0.064 0.001–2.866 0.156
Sex (male/female) 10.89 1.051–112.832 0.045 2.665 0.252–28.180 0.415 
Stage (stageII,III/stageI) 14.39 1.369–151.338 0.026 6.632 0.197–222.796 0.291 
MCPyV-positive/-negative 0.03 0.004–0.207 < 0.001 0.025 0.002–0.346 0.006 
AID  H-score (> 160 vs ≤ 160) 1.04 0.208–5.162 0.966 2.467 0.273–22.286 0.421 
NF-κB p65 (phospho S536)H-score 
(> 65 vs ≤ 65) 1.43 0.324–6.315 0.636 1.401 0.200–9.798 0.734 
PAX5  H-score (> 130 vs ≤ 130) 2.40 0.426–13.536 0.321 18.006 0.938–345.730 0.055 
c-Myb  H-score (> 160 vs ≤ 160) 4.43 0.697–28.102 0.115 0.846 0.078–9.209 0.891 
AID, activation-induced cytidine deaminase; CI, confidence interval; c-Myb, a member of MYV family; HR, hazard ratio; MCC, Merkel 
cell carcinoma; MCPyV, Merkel cell polyomavirus; NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cells; PAX5, Paired 
Box 5; y.o., years old.
Pathogenic bacterial or viral factors and subsequent 
inflammatory reactions in H. pylori-related gastritis, 
chronic viral hepatitis, Barrett’s esophagus, and inflam-
matory bowel disease lead to the aberrant expression 
of AID in various epithelial cells via NF-κB activation, 
which causes the accumulation of genetic alterations in 
tumor-related genes.11 
 Most MCCs are MCPyV-infected tumor. Our 
study revealed that the aberrant expression of AID was 
significantly lower in MCPyV-positive MCCs than in 
MCPyV-negative MCCs (P = 0.026), although aberrant 
NF-κB p65 (phospho S536) expression (an AID-en-
hancer) was significantly higher in MCPyV-positive 
MCCs than in MCPyV-negative MCCs (P = 0.034). 
Aberrant expression of PAX5 (an AID-enhancer) and 
c-Myb (an AID-silencer) was not significantly different 
between MCPyV-positive and –negative MCCs, and 
also that MCPyV was likely to be involved in patho-
gen-induced AID expression via NF-κB activation in 
MCPyV-positive MCCs. These results suggest that 
the genomic modulation of tumor-related genes by 
MCPyV-induced AID expression is a causative mecha-
nism in the carcinogenesis of MCPyV-positive MCCs. 
However, Unexpectedly, the aberrant expression of AID 
was higher in MCPyV-negative MCCs with lower NF-
κB p65 (phospho S536) expression than in MCPyV-pos-
itive MCCs with higher NF-κB p65 (phospho S536) 
expression (P = 0.026). This finding indicates that addi-
tional factors may modulate expression level of AID; the 
other enhancers and/or silencers of AID may influence 
the expression of AID in MCCs. Recently, in fact, it is 
known that not only NF-κB, but also Homeobox protein 
C4 may promote the transcription of AID and E2f, a 
transcription factor targeted by Rb protein, is also a si-
lencer for AID.12 
 Cimino PJ et al20 performed whole exome se-
quencing on five MCPyV-positive cases and three 
MCPyV-negative cases and the retinoblastoma gene 
(RB1) was found to have nonsense truncating gene 
mutations in all three MCPyV-negative cases, whereas 
no such mutations were found in the MCPyV-positive 
cases. While MCPyV-positive MCCs is believed to 
undergo retinoblastoma dysregulation through viral 
large T antigen expression, their findings demonstrate 
that somatic mutations of RB1 in MCPyV-negative 
MCCs lead to retinoblastoma dysregulation through an 
alternative pathway. Harms PW et al performed inte-
grative sequencing on 16 cases of MCC and reported 
152
M. Matsushita et al.
that MCPyV-negative tumors displayed high overall 
mutation burden (10.09 ± 2.32 mutations/Mb) and were 
characterized by a prominent UV-signature pattern with 
C > T transitions comprising 85% of mutations, while 
mutation burden was low in MCPyV-positive tumors 
(0.40 ± 0.09 mutations/Mb) and lacked a UV signature. 
Recent exome sequencing studies on 49 MCCs18 also 
reconfirmed the dramatical differences of gene muta-
tions between MCPyV-positive and –negative MCCs; 
MCPyV-negative MCCs have a high mutation burden 
(median of 1121 somatic single nucleotide variants 
(SSNVs) per-exome) with frequent mutations in RB1 
and TP53 and additional damaging mutations in genes 
in the chromatin modification (ASXL1, MLL2, and 
MLL3), JNK (MAP3K1 and TRAF7), and DNA-dam-
age pathways (ATM, MSH2, and BRCA1). In contrast, 
MCPyV-positive MCCs harbor few SSNVs (median of 
12.5 SSNVs/tumor) with none in the genes listed above. 
Goh et al.18 also reconfirmed that MCPyV-negative 
MCCs were significantly enriched for C > T transitions 
(median of 86% of SSNVs in MCPyV-negative MCCs 
vs. 47% of SSNVs in MCPyV-positive MCCs; P = 3.1E-
7; two-sided Mann-Whitney test) and hypothesized that 
the enrichment of C > T transitions were a result of ul-
traviolet light (UV), because MCCs develop on the skin. 
However, they also pointed that C > T transitions can 
be caused by other mechanisms, e.g. such as aging and 
impaired mismatch repair21 and reported that a median 
of 66% of SSNVs per MCPyV-negative MCC could be 
attributed to UV exposure. 
 Recent high-throughput sequencing of large num-
bers of human cancer genomes showed that mutations at 
cytosine residues, particularly C to T transitions, are the 
most prevalent mutations in human cancer, highlight-
ing enzymatic deamination of cytosine to uracil like 
AID-induced U:G mismatches in DNA as a potential 
source of mutagenesis.21 AID-induced U:G mismatches 
from C:G in DNA are partially transited by replication 
over deoxyuridines to T:A, resulting in AID-induced 
C > T transition (C:G to T:A transition). Despite AID’s 
important physiological functions for SHM and CSR 
in Ig gene, these host defense mechanisms entail a 
high risk of potentially carcinogenic off-target genom-
ic mutagenesis. Our finding of the significantly higher 
aberrant AID expression in MCPyV-negative MCCs 
than in MCPyV-positive MCCs (P = 0.026) is, compat-
ible with the reported exome sequencing data17, 18 that 
MCPyV-negative MCCs have an extremely higher mu-
tation burden than MCPyV-positive ones, although UV 
looks like a major mutagenic factor in MCPyV-negative 
MCCs. 
 In conclusion, lower expression of AID and higher 
expression of NF-κB p65 (phospho S536) were sig-
nificantly associated with MCPyV-positive MCCs. 
While pathogen (MCPyV)-induced AID expression 
through upregulation of NF-κB may be relevant to 
carcinogenesis of MCPyV-positive MCCs, the other 
regulating factors for AID may influence the higher 
AID expression in MCPyV-negative MCCs. The higher 
aberrant expression of AID, a mutagenic enzyme, and 
more frequent AID-related mutation signatures ob-
served in MCPyV-negative MCCs associated with poor 
prognosis in this study is compatible with the fact that 
MCPyV-negative MCCs have an extremely higher muta-
tion burden than MCPyV-positive ones. 
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